Literature DB >> 23041021

Novel coronavirus associated with severe respiratory disease: case definition and public health measures.

N Danielsson1, M Catchpole.   

Abstract

Two cases of rapidly progressive acute respiratory infection in adults associated with a novel coronavirus have generated an international public health response. The two infections were acquired three months apart, probably in Saudi Arabia and Qatar. An interim case definition has been elaborated and was published on the World Health Organization website on 25 September 2012.

Entities:  

Mesh：

Year:  2012        PMID： 23041021     DOI： 10.2807/ese.17.39.20282-en

Source DB:  PubMed          Journal:  Euro Surveill        ISSN： 1025-496X


  19 in total

1.  Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.

Authors:  Kazuya Shirato; Miyuki Kawase; Shutoku Matsuyama
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

2.  SARS hCoV papain-like protease is a unique Lys48 linkage-specific di-distributive deubiquitinating enzyme.

Authors:  Miklós Békés; Wioletta Rut; Paulina Kasperkiewicz; Monique P C Mulder; Huib Ovaa; Marcin Drag; Christopher D Lima; Tony T Huang
Journal:  Biochem J       Date:  2015-06-01       Impact factor: 3.857

3.  Incubation period as part of the case definition of severe respiratory illness caused by a novel coronavirus.

Authors:  H Nishiura; K Mizumoto; K Ejima; Y Zhong; Bj Cowling; R Omori
Journal:  Euro Surveill       Date:  2012-10-18

4.  Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus.

Authors:  Florian Zielecki; Michaela Weber; Markus Eickmann; Larissa Spiegelberg; Ali Moh Zaki; Mikhail Matrosovich; Stephan Becker; Friedemann Weber
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

5.  Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures.

Authors:  Renee W Y Chan; Michael C W Chan; Sudhakar Agnihothram; Louisa L Y Chan; Denise I T Kuok; Joanne H M Fong; Y Guan; Leo L M Poon; Ralph S Baric; John M Nicholls; J S Malik Peiris
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

6.  Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate.

Authors:  Fernando Almazán; Marta L DeDiego; Isabel Sola; Sonia Zuñiga; Jose L Nieto-Torres; Silvia Marquez-Jurado; German Andrés; Luis Enjuanes
Journal:  mBio       Date:  2013-09-10       Impact factor: 7.867

7.  X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases.

Authors:  Yahira M Báez-Santos; Scott J Barraza; Michael W Wilson; Michael P Agius; Anna M Mielech; Nicole M Davis; Susan C Baker; Scott D Larsen; Andrew D Mesecar
Journal:  J Med Chem       Date:  2014-03-14       Impact factor: 7.446

8.  Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis.

Authors:  Jose L Nieto-Torres; Marta L DeDiego; Carmina Verdiá-Báguena; Jose M Jimenez-Guardeño; Jose A Regla-Nava; Raul Fernandez-Delgado; Carlos Castaño-Rodriguez; Antonio Alcaraz; Jaume Torres; Vicente M Aguilella; Luis Enjuanes
Journal:  PLoS Pathog       Date:  2014-05-01       Impact factor: 6.823

9.  Middle East Respiratory Syndrome Coronavirus Gene 5 Modulates Pathogenesis in Mice.

Authors:  Javier Gutierrez-Alvarez; Li Wang; Raul Fernandez-Delgado; Kun Li; Paul B McCray; Stanley Perlman; Isabel Sola; Sonia Zuñiga; Luis Enjuanes
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

10.  Detection of Middle East respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP).

Authors:  Kazuya Shirato; Takuya Yano; Syouhei Senba; Shigehiro Akachi; Takashi Kobayashi; Takamichi Nishinaka; Tsugunori Notomi; Shutoku Matsuyama
Journal:  Virol J       Date:  2014-08-08       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.